Alternatively, an inhibitor might suffer a loss-of-function mutation, lose its ability to regulate signalling and lose its functions as a tumour suppressor. Both types of change in Wnt signalling ...

Many components of the Wnt pathway are theoretically targets for new drug discovery. Selecting a tissue-appropriate target may be an important consideration in order to limit toxicity. Targeting ...

With these issues behind us, we can now fully focus on our mission of advancing our novel PARP/Wnt inhibitor through the clinical development plans we have already announced.” As previously ...

Cash and cash receivable balance of $20.9 million as of December 31, 2024, expected to fund operations, including clinical activities ...

Background Development of diffuse-type gastric cancer (DGC) starts with intramucosal lesions that are primarily composed of ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway ...

The research reveals that MAFB and CCAAT/enhancer-binding protein alpha (CEBPA) regulate urothelial cell growth via the Wnt/β-catenin signaling pathway, offering new insights into the genetic ...

Surrozen will focus its Wnt biology expertise and Wnt signal modulation antibody technologies on its ophthalmology programs including development of new treatment options for retinopathies. Other ...